Clinical Trial Update: Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial update evaluating Sandostatin (octreotide) in patients with castration-resistant prostate cancer, focusing on uptake of 68Ga-DO…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Sandostatin (Octreotide acetate)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Prostatic Neoplasms | Phase 1 | Status: UNKNOWN